BiotechTube
Akiram Therapeutics

Akiram Therapeutics

Stockholm, Sweden· Est.
akiramtherapeutics.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Akiram Therapeutics is a Stockholm-based biotech founded in 2022, advancing a targeted radioimmunotherapy platform for metastatic solid cancers. The company's lead candidate, AKIR001, is already in Phase I clinical trials, with promising preclinical data featured in leading journals. Akiram combines expertise in radiation sciences, oncology, and drug development to create first-in-class radiopharmaceuticals for patients with limited treatment options. The company is privately held, pre-revenue, and actively seeking investment and partnerships to advance its clinical programs.

OncologySolid Tumors

Technology Platform

Targeted radioimmunotherapy platform combining tumor-specific antibodies with diagnostic and therapeutic radionuclides for a theranostic approach to solid cancers.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global radiopharmaceutical market is rapidly expanding, with significant unmet need in metastatic solid tumors.
Akiram's theranostic, antibody-based approach could offer advantages in targeting difficult cancers, positioning it for partnerships or acquisition upon clinical validation.
Success could establish a new treatment paradigm for patients with limited options.

Risk Factors

Key risks include clinical failure in ongoing Phase I trials, the significant technical and regulatory challenges of manufacturing and distributing short-lived radiopharmaceuticals, and intense competition in the rapidly evolving targeted radiotherapy space from larger, well-resourced companies.

Competitive Landscape

Akiram competes in the targeted radiopharmaceutical space against giants like Novartis (Pluvicto, Lutathera) and a growing field of biotechs (e.g., RayzeBio, Fusion Pharmaceuticals, Aktis Oncology). Its focus on antibody-based RIT for solid tumors differentiates it from many players using small-molecule ligands, but it faces competition from other RIT developers and must prove superior targeting or efficacy.

More companies in Radiopharmaceuticals →More companies in Sweden →